Provided by Tiger Trade Technology Pte. Ltd.

Sagimet Biosciences Inc.

10.99
+0.49004.67%
Post-market: 11.250.2593+2.36%19:57 EDT
Volume:1.80M
Turnover:19.56M
Market Cap:683.12M
PE:-8.80
High:11.06
Open:10.51
Low:10.51
Close:10.50
52wk High:11.15
52wk Low:4.50
Shares:62.16M
Float Shares:55.78M
Volume Ratio:2.30
T/O Rate:3.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2490
EPS(LYR):-1.5800
ROE:-24.37%
ROA:-16.41%
PB:2.67
PE(LYR):-6.96

Loading ...

Sagimet Biosciences Grants New Performance-Based Executive Equity Awards

TIPRANKS
·
Jun 04

Sagimet Biosciences grants CEO David Happel 300,000 stock options, 300,000 performance-based RSUs

Reuters
·
Jun 04

UK's Mhra: Resmetirom (Rezdiffra) Authorised to Treat Metabolic Dysfunction-Associated Steatohepatitis (Mash) in Adults

THOMSON REUTERS
·
Jun 03

Sagimet says Phase 1 trial shows denifanstat-resmetirom combo cuts LDL cholesterol in healthy adults

Reuters
·
May 27

Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH

GlobeNewswire
·
May 27

Sagimet Biosciences, Inc. Class A (SGMT) Receives a Buy from H.C. Wainwright

TIPRANKS
·
May 27

Sagimet Biosciences Is Maintained at Market Outperform by Citizens

Dow Jones
·
May 19

Sagimet Biosciences price target lowered to $12 from $35 at Citizens

TIPRANKS
·
May 19

Sagimet Biosciences files Form 3 for Chief Medical Officer Andreas Grauer

Reuters
·
May 15

Sagimet Biosciences, Inc. Class A (SGMT) Receives a Rating Update from a Top Analyst

TIPRANKS
·
May 14

Sagimet Biosciences price target lowered to $28 from $37 at Clear Street

TIPRANKS
·
May 14

Sagimet Maintained at Buy as Strong Cash Runway and Advancing Acne Franchise Support Unchanged $28 Price Target

TIPRANKS
·
May 14

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 13

Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

GlobeNewswire
·
May 13

Sagimet Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

BRIEF-Sagimet Biosciences Reports First Quarter 2026 Financial Results And Provides Corporate Updates

Reuters
·
May 12

Sagimet Biosciences Q1 EPS $(0.33) Beats $(0.36) Estimate

Benzinga Earnings
·
May 12

Sagimet Q1 FY26 net loss narrows to $10.7 million; R&D expense drops to $7 million

Reuters
·
May 12

Press Release: Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Dow Jones
·
May 12

Sagimet plans U.S. Phase 3 denifanstat acne trial start in H2 2026

Reuters
·
May 11